Trial · NCT07099014
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | A composite hierarchical outcome composed of two components: 1) mortality, 2) number of days alive without invasive mechanical ventilation within 28 days following ECMO initiation | Day 28 | * Each patient will be compared with every other patient in the study and assigned a score (tie: 0, win: +1, loss: -1) for each pairwise comparison based on whom fared better. * If one patient survived on day 28 and the other did not, scores of +1 and -1 will be assigned, respectively, for that pairwise comparison. If both patients in the pairwise comparison survived at day 28, the assigned score will depend on which patient had more days free from mechanical ventilation: the patient with more ventilator-free days alive at day 28 will receive a score of +1, while the patient with fewer days will receive a score of -1. If both patients survived and had the same number of ventilator-free days on day 28, and if both patients died, they will be both assigned a score of 0 for that pairwise comparison. For each patient, scores for all pairwise comparisons will be summed, resulting in a cumulative score. |
| Secondary | Overall survival | Day 28 | |
| Secondary | Number of ECMO-free days | Day 14, Day 28 | |
| Secondary | Number of inotropes-free days | Day 14, Day 28 | |
| Secondary | Number of ICU-free days | Day 28 | |
| Secondary | Number of ventilation-free days | Day 14, Day 28 | |
| Secondary | incidence of delirium | Day 28 | |
| Secondary | Opioids daily consumption during invasive mechanical ventilation | Day 14 | |
| Secondary | Consumption of propofol | Day 14 | consumption during invasive mechanical ventilation |
| Secondary | Consumption of midazolam | Day 14 | consumption during invasive mechanical ventilation |
| Secondary | Consumption of Clonidine | Day 14 | consumption during invasive mechanical ventilation |
| Secondary | Consumption of Haloperidol | Day 14 | consumption during invasive mechanical ventilation |
| Secondary | Consumption of dexmedetomidine | Day 14 | consumption during invasive mechanical ventilation |
| Secondary | Incidence of drugs side effects (refractory hypertension, malignant hyperthermia) | From randomization to Day 28 | assess the safety of prolonged isoflurane inhalation during ECMO |
| Secondary | Number of participants requiring ventricular assist device | Day 28 | |
| Secondary | Number of participants undergoing heart transplantation | Day 28 | |
| Secondary | Rate of side effects possibly linked to ineffective sedation (self-extubation, accidental ECMO decannulation, catheter withdrawal) | From randomization to Day 28 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07099014/registered